Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

• Status: RECRUITING
• Trial end date: 2027-02-01

Summary

This single-arm, open label study is aimed to assess efficacy and safety of dolutegravir plus lamivudine as a switch strategy among TGW with HIV receiving suppresive antiretroviral therapy.

• Phase: PHASE4

Details

• Lead Sponsor: UBATEC
• Collaborators: Hospital Fernandez; ViiV Healthcare
• Treatments: dolutegravir; Lamivudine